IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

...

Related Keywords

United States ,China ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,Japan ,Cambridge ,Cambridgeshire ,America ,American ,Suresh Senan ,Susan Galbraith ,Daiichi Sankyo ,Lungevity Foundation ,World Health Organization ,International Agency For Research On Cancer ,American Cancer Society ,National Cancer Institute ,Amsterdam University Medical Center ,Astrazeneca ,Lung Ambition Alliance ,Executive Vice President ,Fatal Immune Mediated Adverse ,Mediated Nephritis ,Stevens Johnson Syndrome ,Full Prescribing Information ,Medication Guide ,South America ,Rare Diseases ,Cell Lung ,Accessed April ,Relapsed Small Cell Lung Cancer ,Small Cell Lung Cancer ,Mixed Methods Study ,International Agency ,Lung Fact ,Treatment Choices ,Small Cell Lung ,